Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Rioghna R. Pittock(Mayo Clinic), Maria Vassilaki(Mayo Clinic), Anna Castillo(Mayo Clinic), Vijay K. Ramanan(Mayo Clinic in Arizona), Prashanthi Vemuri(Mayo Clinic in Arizona), Ronald C. Petersen(Mayo Clinic in Arizona), Walter K. Kremers(Mayo Clinic), David S. Knopman(Mayo Clinic), Jonathan Graff-Radford(Mayo Clinic), Val J. Lowe(Mayo Clinic), Jeremiah A. Aakre(Mayo Clinic), Clifford R. Jack(Mayo Clinic)
Cited by 138
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment as a diagnostic entity
|Journal of Internal Medicine|2004|7.8k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k